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Abstract
Background: Adiponectin critically contributes to metabolic homeostasis, especially by insulin-sensitizing action.
Gestational diabetes mellitus (GDM) is characterized by insulin resistance leading to materno-fetal hyperglycemia
and detrimental birth outcomes. By investigating paired subcutaneous (SAT) and visceral adipose tissue (VAT) as
well as blood (cell) samples of GDM-affected (n = 25) vs. matched control (n = 30) mother-child dyads of the
prospective “EaCH” cohort study, we addressed whether alterations of adiponectin plasma, mRNA, and DNA
methylation levels are associated with GDM and offspring characteristics.
Results: Hypoadiponectinemia was present in women with GDM, even after adjustment for body mass index
(BMI). This was accompanied by significantly decreased mRNA levels in both SAT and VAT (P < 0.05), independent
of BMI. Maternal plasma adiponectin showed inverse relations with glucose and homeostatic model assessment
of insulin resistance (both P < 0.01). In parallel to reduced mRNA expression in GDM, significant (P < 0.05) yet
small alterations in locus-specific DNA methylation were observed in maternal fat (~ 2%) and blood cells (~ 1%).
While newborn adiponectin levels were similar between groups, DNA methylation in GDM offspring was variously
altered (~ 1–4%; P < 0.05).
Conclusions: Reduced adiponectin seems to be a pathogenic co-factor in GDM, even independent of BMI, affecting
materno-fetal metabolism. While altered maternal DNA methylation patterns appear rather marginally involved,
functional, diagnostic, and/or predictive implications of cord blood DNA methylation should be further evaluated.
Keywords: Gestational diabetes mellitus, Epigenetics, DNA methylation, Adiponectin, Adipose tissue, Blood cells,
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Background
Gestational diabetes mellitus (GDM) is one of the most
frequent metabolic disorders in pregnancy affecting
meanwhile > 10% of women in Western countries [1–3].
Both increased peripheral insulin resistance and failed
compensation of insulin need are hallmarks of GDM [4].
While causes for these characteristics remain unclear,
other endocrine factors are potentially contributing.
Adiponectin (ADIPOQ) is a key hormone in energy
metabolism, critically involved in maintaining insulin
sensitivity, glucose, and lipid homeostasis [5]. Accord-
ingly, hypoadiponectinemia has been observed in insulin
resistance, type 2 diabetes, GDM, and obesity [6, 7].
Interestingly, studies suggest that low adiponectin levels
in early pregnancy represent a risk marker for GDM de-
velopment [8], and the clinical relevance has been de-
bated [9]. Furthermore, hypoadiponectinemia during
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gestation and/or post-partum is associated with poorer
maternal insulin sensitivity after delivery and may pre-
dict future development of type 2 diabetes [10, 11]. In a
normal pregnancy, maternal circulating adiponectin
levels progressively decline particularly in the third tri-
mester along with increasing insulin resistance [12].
Hence, a critical role of adiponectin in gestational meta-
bolic adaptations has been proposed [13]. Adiponectin
cannot cross the placenta but is able to influence
materno-fetal nutrient transport directly by modulating
insulin signaling in syncytiotrophoblast cells [14]. Col-
lectively, adiponectin appears to be not only a specific
factor for regulating materno-fetal metabolism but also
an important candidate in GDM pathophysiology.
Adipose tissue represents the main source of adipo-
nectin [5]. It has been proposed that production is
higher in subcutaneous (SAT) than in visceral adipose
tissue (VAT) [15–18]. In GDM, only two studies so far
investigated ADIPOQ gene expression and found de-
creased mRNA levels in adipose tissues [19, 20]. How-
ever, both studies were rather limited in sample size, one
had only access to SAT biopsies [19], or their group
comparisons did not reach statistical significance in SAT
and VAT, despite an even significant higher body mass
index (BMI) in the GDM group [20]. Thus, it should be
further evaluated if ADIPOQ gene expression is indeed al-
tered in patients with GDM, in comparison to BMI-
matched controls, as differential adiposity states impede
the interpretation of a genuine GDM effect. Furthermore,
if mRNA levels are affected, causal factors should be ex-
plored to gain more insights into the potential mecha-
nisms of GDM.
Regulation of ADIPOQ mRNA expression is complex,
and a variety of transcription factors has been identified
[21]. Additionally, recent studies suggest a major role of
epigenetic mechanisms, namely DNA methylation, in ADI-
POQ transcription [22, 23]. DNA methylation occurs
mainly on cytosine-guanine (CpG) dinucleotides. In gen-
eral, increased methylation is commonly interpreted to be
associated with repression of gene transcription; however,
underlying mechanisms are more complex and certainly
depend on the genomic/genetic location [24]. While pat-
terns of DNA methylation can occur in a tissue-specific
manner, they can be similar in other tissues, e.g., circulat-
ing blood cells, which would allow easy access for experi-
mental and clinical purposes. Evaluation of potential
functional relevance of DNA methylation signatures in the
tissue of origin as well as cross-tissue reliability appears
critical in this regard. Accordingly, DNA methylation rep-
resents a mechanism through which ADIPOQ transcrip-
tion might be affected, but studies are lacking so far
investigating this in adipose tissue from GDM patients.
Offspring of women with GDM are at increased risk for
the development of glucose intolerance and associated
disturbances later in life [4, 25]. The main (molecular)
causes of this phenomenon remain unclear, but epigenetic
mechanisms are increasingly suggested as a functional
transmitter. Specifically, early in-life alterations of the
DNA methylation pattern might lead to long-term dysreg-
ulation of gene expression, e.g., for ADIPOQ. Bouchard et
al. [22] showed that maternal glucose levels at GDM
screening are associated with placental DNA methylation
of ADIPOQ. This may indicate that materno-fetal (hyper)-
glycemia is involved in the programming of DNA methy-
lation signatures. The placenta, however, does not appear
to represent a key source tissue of adiponectin [9, 14, 20].
Therefore, further cross-tissue studies may provide add-
itional information on whether and where ADIPOQ DNA
methylation patterns are altered in the context of hyper-
glycemic materno-fetal conditions.
In the present study, we therefore analyzed adipo-
nectin plasma levels and gene expression in SAT and
VAT biopsies from women with GDM and matched
normal glucose tolerant (NGT) controls. Further-
more, we investigated whether DNA methylation is
associated with mRNA levels and shows consistency
across maternal adipose tissues and blood (MB) cells.
Finally, we determined DNA methylation of ADIPOQ
in cord blood (CB) cells to evaluate the changes in




Table 1 shows general and specific characteristics of
mothers and newborns. On average, both the GDM and
NGT groups were overweight before pregnancy. Total
gestational weight gain (GWG) was similar between the
groups, while net GWG was significantly lower in dia-
betic subjects. At delivery, women of both groups
showed comparable BMI. In GDM, maternal metabolic
and hormonal state was still altered at the end of preg-
nancy as compared to controls. Fasting blood glucose,
insulin, C-peptide, and homeostatic model assessment of
insulin resistance (HOMA-IR) were higher in women
with GDM. In contrast, plasma adiponectin was signifi-
cantly lower in the GDM group (Table 1). This was inde-
pendent of maternal BMI (adjusted for prepregnancy
BMI, P = 0.006; adjusted for BMI at delivery, P = 0.004).
Across the whole cohort (n = 55), maternal plasma
adiponectin correlated inversely with both BMI before
and at the end of pregnancy, but not with total or net
GWG, respectively (Table 1). Inverse relationships
were observed between maternal adiponectin vs. glu-
cose, C-peptide, insulin, and HOMA-IR. In addition,
MB adiponectin was negatively related to CB glucose,
C-peptide, and triglyceride levels.
Ott et al. Clinical Epigenetics          (2018) 10:131 Page 2 of 12
Table 1 General and specific characteristics of study participants and relations with maternal blood adiponectin at delivery




Age (years) 32.5 ± 1.0 32.4 ± 0.9 0.919 0.17 (0.210)
Ethnic origin—n (%) 1.000 n.a.
European 20 (66.7) 16 (64.0)
Non-European 10 (33.3) 9 (36.0)
Socio-economic status—n (%)† 0.215 n.a.
Lower SES category 21 (84.0) 20 (66.7)
Higher SES category 4 (16.0) 10 (33.3)
Smoking in pregnancy (any)—n (%) 7 (23.3) 3 (12.0) 0.318 n.a.
Nulliparous—n (%) 4 (13.3) 4 (16.0) 1.000 n.a.
Height (cm) 167.0 ± 1.2 164.6 ± 1.3 0.246 0.23 (0.100)
Prepregnancy weight (kg) 73.7 ± 3.9 77.7 ± 3.8 0.257 − 0.22 (0.114)
Prepregnancy BMI (kg/m2) 26.4 ± 1.3 28.6 ± 1.3 0.105 − 0.31 (0.021)
Total GWG (kg) 17.2 ± 1.2 14.4 ± 1.4 0.127 0.03 (0.848)
Net GWG (kg) 13.9 ± 1.2 9.9 ± 1.4 0.028 0.14 (0.363)
BMI at delivery (kg/m2) 32.5 ± 1.5 34.0 ± 1.2 0.124 − 0.31 (0.023)
Blood glucose at oGTT (mg/dL)
Fasting 79.5 ± 1.7 99.0 ± 5.4 < 0.001 − 0.26 (0.086)
1 h 120.9 ± 6.3 207.0 ± 7.2 < 0.001 − 0.30 (0.041)
2 h 90.3 ± 4.2 161.4 ± 9.7 < 0.001 − 0.18 (0.243)
Area under the curve (mg/dL h) 205.8 ± 8.2 337.3 ± 13.5 < 0.001 − 0.28 (0.058)
Gestational age at delivery (weeks) 38.3 ± 0.1 37.8 ± 0.2 0.028 0.03 (0.841)
Mode of delivery—n (%) 1.000 n.a.
Primary cesarean section 9 (30.0) 7 (28.0)
Repeat cesarean section 21 (70.0) 18 (72.0)
Maternal fasting plasma levels at delivery
Adiponectin (μg/mL)‡ 9.9 ± 0.8 6.7 ± 0.5 0.002 n.a.
Glucose (mg/dL) 72.5 ± 2.0 85.0 ± 1.2 < 0.001 − 0.37 (0.007)
Insulin (μU/mL) 22.3 ± 2.7 40.1 ± 8.2 0.217 − 0.33 (0.014)
HOMA-IR 3.6 ± 0.3 8.3 ± 1.7 0.037 − 0.36 (0.009)
C-peptide (ng/mL) 2.0 ± 0.2 4.9 ± 0.7 < 0.001 − 0.53 (< 0.001)
Leptin (ng/mL) 28.9 ± 3.5 18.0 ± 2.6 0.017 0.04 (0.772)
Triglycerides (mmol/L) 2.4 ± 0.1 2.3 ± 0.1 0.554 0.11 (0.413)
Birth outcome/newborn
Female sex—n (%) 18 (60.0) 11 (44.0) 0.285 n.a.
Placental weight (g) 658.7 ± 28.4 612.5 ± 37.8 0.337 − 0.15 (0.328)
Birth weight (g) 3368 ± 87 3578 ± 82 0.038 − 0.22 (0.113)
Birth length (cm) 51.1 ± 0.5 50.9 ± 0.3 0.890 − 0.03 (0.858)
Relative birth weight (g/cm) 65.8 ± 1.3 70.3 ± 1.5 0.022 − 0.23 (0.098)
Macrosomia—n (%) 3 (10.0) 4 (16.0) 0.689 n.a.
LGA—n (%) 3 (10.0) 9 (36.0) 0.026 n.a.
Hypoglycemia—n (%) 1 (3.6) 6 (24.0) 0.043 n.a.
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Birth and newborn outcomes
Offspring of GDM women were significantly heavier at
birth but similar in length compared to newborns of the
NGT group (Table 1). CB plasma levels of glucose, insu-
lin, C-peptide, and triglycerides were significantly in-
creased in newborns of GDM mothers, accompanied by
elevated HOMA-IR and leptin levels. There was no sig-
nificant difference of CB adiponectin concentrations be-
tween the groups. Furthermore, female and male neonates
showed equal amounts of CB adiponectin (female 27.8 ±
1.4 μg/mL vs. male 26.3 ± 2.5 μg/mL, P = 0.299). In the
whole cohort, no correlations were present between CB
adiponectin and newborns’ anthropometry or CB metabo-
lites/hormones. However, sex-specific subgroup analyses
revealed positive associations between CB adiponectin vs.
insulin and HOMA-IR in male neonates (insulin, r = 0.41,
P = 0.037; HOMA-IR, r = 0.41, P = 0.042).
ADIPOQ gene expression in maternal adipose tissues
In both adipose tissue types, gene expression of ADIPOQ
was significantly reduced in women with GDM (Fig. 1a, b).
On average, diabetic subjects had 20–30% less mRNA
levels compared to controls, with the difference higher in
VAT than SAT. Again, these group differences were even
independent of maternal BMI (adjusted for prepregnancy
BMI—SAT: P = 0.049, VAT: P = 0.008, SAT+VAT: P =
0.002; adjusted for BMI at delivery—SAT: P = 0.037, VAT:
P = 0.006, SAT+VAT: P = 0.001). Across the whole cohort,
VAT, but not SAT, and ADIPOQ mRNA levels were in-
versely associated with maternal glucose concentrations at
oral glucose tolerance test (oGTT) and at delivery (fasting
glucose at oGTT: r = − 0.33, P = 0.029; area under the
curve of glucose (AUCG) at oGTT: r = − 0.43, P = 0.004;
fasting glucose at delivery: r = − 0.29, P = 0.040). Gene ex-
pression in both fat depots was positively associated with
maternal circulating adiponectin levels across the whole
cohort (Fig. 1c–e), irrespective of the BMI (adjusted for
prepregnancy BMI—SAT: R = 0.44, P = 0.001, VAT: R =
0.34, P = 0.017; SAT+VAT: R = 0.51, P < 0.001; and adjusted
for BMI at delivery—SAT: R = 0.45, P = 0.001, VAT: R =
0.35, P = 0.015; SAT+VAT: R = 0.52, P < 0.001). SAT
plus VAT mRNA levels showed the strongest correla-
tions with plasma adiponectin.
DNA methylation at the ADIPOQ gene locus in maternal
tissues
The overall DNA methylation pattern of the analyzed re-
gions at the ADIPOQ gene locus was similar in SAT and
VAT (Fig. 2b, c). All investigated CpG sites (n = 10) had
moderate to high methylation levels (> 50%). Region R1
was hypermethylated as compared to R2 and R3. A gen-
erally higher variability of DNA methylation was ob-
served in R2 and R3 in both fat depots.
In SAT, DNA methylation was consistent between
both groups. Statistically, only the comparison at R2
CpG2 was close to significance (P = 0.056). Although
similar to SAT regarding the overall pattern, methylation
in VAT showed slightly less variability in R2 and R3. By
groups, methylation of R3 in VAT appeared tighter in
GDM subjects. Furthermore, DNA methylation of the two
CpG sites was significantly altered in VAT of women with
GDM vs. NGT. Compared to controls, R1 CpG4 was lower
and R3 CpG1 higher methylated in VAT of the diabetic
group (Fig. 2c). The mean methylation difference was
around 2.1–2.4%. To evaluate the potential functional rele-
vance of these two CpG sites, correlation analyses between
DNA methylation at R1 CpG4 and R3 CpG1 and VAT
gene expression were performed (Fig. 2f, g). Here, only the
position R3 CpG1 showed a significant inverse relationship
with mRNA levels. Further inverse correlations were found
Table 1 General and specific characteristics of study participants and relations with maternal blood adiponectin at delivery
(Continued)
NGT GDM P value* Spearman’s r vs. MB adiponectin
r (P value*)
Cord blood plasma levels
Adiponectin (μg/mL) 25.8 ± 1.6 28.5 ± 2.4 0.488 0.18 (0.182)
Glucose (mg/dL) 61.6 ± 2.0 72.0 ± 1.9 0.001 − 0.33 (0.015)
Insulin (μU/mL) 19.2 ± 2.0 26.9 ± 2.9 0.042 − 0.13 (0.366)
HOMA-IR 3.1 ± 0.4 5.0 ± 0.6 0.003 − 0.22 (0.117)
C-peptide (ng/mL) 1.0 ± 0.1 1.6 ± 0.1 < 0.001 − 0.31 (0.023)
Leptin (ng/mL) 10.8 ± 1.7 15.2 ± 2.6 0.247 − 0.21 (0.130)
Triglycerides (mmol/L) 1.1 ± 0.1 1.8 ± 0.1 < 0.001 −0.40 (0.003)
Data are means ± SEM or n (%)
NGT normal glucose tolerance, GDM gestational diabetes mellitus, MB maternal blood, n.a. not applicable, SES socio-economic status, BMI body mass index, GWG
gestational weight gain, oGTT oral glucose tolerance test, HOMA-IR homeostatic model assessment of insulin resistance, LGA large-for-gestational age newborn
*Statistical significant (P value < 0.05)
†SES was categorized as previously described [36]
‡Continued to be significantly different between the groups after adjustment for prepregnancy BMI (P = 0.006) and BMI at delivery (P = 0.004)
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between gene expression and single CpG sites and/or
mean methylation levels regarding R2 and R3, but not R1,
across both fat depots. For example, the means of R2 and
R3 were negatively associated with respective mRNA levels
(SAT—R2 mean: R = − 0.31, P = 0.030, R3 mean: R = − 0.40,
P = 0.008; VAT—R2 mean: R = − 0.33, P = 0.020, R3 mean:
R = − 0.45, P = 0.003). Among all individual CpGs and the
means of R1–R3, VAT CpG1 and CpG2 of R3 DNA methy-
lation showed relations to maternal glucose levels, which
were in a positive direction (CpG1—AUCG at oGTT:
r = 0.37, P = 0.023; fasting glucose at delivery: r = 0.32,
P = 0.034; CpG2—AUCG at oGTT: r = 0.34, P = 0.038).
Despite the similarity of methylation pattern between
SAT and VAT, cross-tissue correlations were rare and
inconsistent. While R1 CpG1 and CpG2 patterns were
inversely associated between both fat types (R1 CpG1:
r = − 0.35, P = 0.014; R1 CpG2: r = − 0.53, P < 0.001),
methylation at R2 CpG1 and R2 mean was related in a
positive manner (R2 CpG1: r = 0.32, P = 0.025; R2 mean:
r = 0.30, P = 0.041).
Fig. 1 Adiponectin mRNA levels in adipose tissues of women with NGT vs. GDM and their relations to plasma adiponectin. Gene expression of
adiponectin (ADIPOQ) normalized to peptidylprolyl isomerase A (PPIA) analyzed in subcutaneous (SAT) and visceral adipose tissues (VAT), respectively, of
normal glucose tolerance women (NGT; open bars; n= 30) vs. women with gestational diabetes mellitus (GDM; red bars; n= 22–25). Sum of expression
of both fat depots (SAT+VAT) is plotted additionally (a–b). Data are means ± SEM, shown as raw data (a) or percentage of NGT levels (b). Pearson’s
correlation coefficients (R) calculating the relationship between maternal blood (MB) adiponectin levels and adipose tissue gene expression data (c–e).
NGT, open circles; GDM, red circles. AU, arbitrary units. *P < 0.05, **P < 0.01
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As compared to adipose tissues, MB was characterized by
overall higher and rather tight methylation pattern (mostly
> 90%; Fig. 2d). With regard to R3, the GDM group showed
less variability compared to women with NGT, as observed
in VAT. Group differences were detected at R1 CpG1, R2
mean, and R3 CpG1 (mean differences around 0.4–1.4%).
Similar to VAT, R3 CpG1 in MB was hypermethylated in
the GDM group. However, no correlation was found be-
tween methylation of VATand MB.
Cord blood DNA methylation at the ADIPOQ gene locus
To evaluate a potential GDM effect on fetal DNA methy-
lation, all regions were analyzed in CB cells, too. Across
all investigated tissues, the CB methylation pattern was
most similar to MB, showing the overall low variability
(Fig. 2e). However, higher variation was observed at R3 in
CB vs. MB, while methylation in CB from GDM-exposed
newborns was more “compact.” In comparison to con-
trols, GDM offspring were characterized by significant
Fig. 2 CpG site-specific DNA methylation analyses at the adiponectin gene locus in adipose tissues and blood cells from mothers with NGT vs.
GDM and their offspring. Schematic illustration of the adiponectin (ADIPOQ) gene locus, including characterized transcription factor binding sites
(e.g., SRE, PPRE, C/EBP), and analyzed DNA methylation assays (R1-R3) (a). Percent DNA methylation is shown for each individual CpG site
(numbering follows 5′ to 3′), analyzed per assay (R1–R3) for subcutaneous adipose tissue (SAT; b), visceral adipose tissue (VAT; c), maternal blood
(MB; d), and cord blood (CB; e) in the normal glucose tolerant (NGT; open boxes; n = 30) vs. gestational diabetes mellitus group (GDM; red boxes;
n = 22–25). Group comparisons in cord blood samples were adjusted for newborn sex. Box-whisker plots show the minimum and maximum
values. Pearson’s correlation coefficients (R) were calculated to determine the relationships between DNA methylation of significant CpG sites and
respective ADIPOQ mRNA levels in VAT across the whole cohort (f, g). Gene expression of ADIPOQ was normalized to peptidylprolyl isomerase A
(PPIA). NGT, open circles; GDM, red circles. AU, arbitrary units. *P < 0.05, **P < 0.01, ***P < 0.001
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hypomethylation at all CpG sites and, accordingly, the
mean of R2 (mean differences around 1%), while signifi-
cant hypermethylation at all R3 CpG sites and the mean
of R3 were observed (mean differences around 1.7–4.0%);
even after adjustment for newborn sex (Fig. 2e). The most
pronounced difference was observed at R3 CpG1, which
followed the same pattern as in MB and VAT by showing
higher methylation in the GDM group.
By analyzing the same CpG positions between ma-
ternal tissues and CB, the only positive correlations
were found with the methylation levels of R3 of MB
(CpG1: r = 0.51, P = 0.001; CpG2: r = 0.43, P = 0.008;
CpG3: r = 0.47, P = 0.003). There were no relationships
present between maternal age, prepregnancy BMI, total
GWG, gestational age, or MB hormones and the CB
methylation levels of these significant different regions.
The mean CB DNA methylation levels of R2 correlated in-
versely with maternal BMI at delivery (r = − 0.31, P = 0.031)
and AUCG at oGTT (r = − 0.38, P = 0.013). On the con-
trary, the mean DNA methylation levels of R3 were unre-
lated to maternal BMI but showed positive associations
with AUCG at oGTT and fasting glucose at delivery
(AUCG at oGTT: r = 0.45, P = 0.004; fasting glucose at de-
livery: r = − 0.44, P = 0.003). Furthermore, Spearman’s cor-
relations revealed significant inverse relationships between
R2 CpG1 and mean R2 methylation vs. (relative) birth
weight (birth weight vs. R2 CpG1: r = − 0.32, P = 0.024;
relative birth weight vs. R2 CpG1: r = − 0.36, P = 0.012; R2
mean: r = − 0.32, P = 0.024). Furthermore, methylation of
R3 CpG1, CpG3, and R3 mean was positively associated
with CB adiponectin (R3 CpG1: r = 0.34, P = 0.024; R3
CpG3: r = 0.38, P = 0.011; R3 mean: r = 0.34, P = 0.022).
Discussion
This study demonstrates that plasma adiponectin and its
gene expression in the two major adipose tissue types is
consistently decreased in women with treated GDM as
compared to matched healthy subjects, even independ-
ent of their BMI. Furthermore, our data indicate that
DNA methylation of previously published regions (i.e.,
R2 and R3) indeed may be involved in respective gene
regulation but are just slightly altered in patients with
GDM. Overall, fat tissue DNA methylation patterns are
not reliably reflected in MB cells. CB ADIPOQ DNA
methylation profiles of R2 and R3, however, are signifi-
cantly altered in affected offspring, irrespective of fetal
sex, and associated with their phenotypic parameters.
The present study confirms that GDM is characterized
by hypoadiponectinemia [7]. In addition, plasma adiponec-
tin levels appear to be more related to the insulin-resistant
state than to the maternal BMI/GWG, decisively specifying
observations from other reports [6, 26]. Interestingly, GDM
was associated here with significantly lower net GWG and
circulating leptin levels at delivery. This may imply less
gestational adipose tissue accretion in these subjects, poten-
tially due to GDM treatment. Thus, although adiposity be-
came apparently reduced in the GDM group, adiponectin
was still significantly decreased in comparison to controls.
This argues in favor of a genuine GDM rather than a BMI
(adiposity) effect. Considering its critical functions in en-
hancing insulin sensitivity and glucose/lipid disposal/oxida-
tion, decreased adiponectin levels therefore probably affect
materno-fetal metabolism and, consequently, nutrient sup-
ply to the fetus in GDM. Indeed, maternal adiponectinemia
was inversely associated with blood glucose and HOMA-IR
in both mothers and newborns. Potentially, this has ad-
verse short- and long-term implications for the GDM
offspring [4, 25].
CB adiponectin levels were similar between the groups
and female/male offspring which support the findings
from other studies [27, 28]. Interestingly, there was a
positive link between CB adiponectin and insulin/insulin
resistance in male offspring, which appears paradox
compared with the adult situation, where adiponectin
levels usually decline with increasing insulin resistance
[6, 12]. However, CB adiponectin has been also sug-
gested as a growth factor in early life [14, 27, 29], which
may involve temporary synergistic effects with insulin.
Fetal insulin is a potent anabolic factor contributing to
higher in utero growth and has also been identified as a
critical hormone for the early “programming” of later
metabolic disease risk [30].
In adults, production of adiponectin is primarily lo-
cated in white adipocytes [5]. Our data revealed reduced
mRNA expression in SAT and VAT of women with
GDM, even after adjustment for BMI. Reduced fat tissue
expression, moreover, obviously affected the circulating
plasma levels, as indicated by correlation analyses. Ex-
pression in both fat depots was associated with plasma
adiponectin, while the relationship with the sum of SAT
+VAT actually was the strongest. Interestingly, a large
number of studies focused on circulating adiponectin
[7], but only two investigated its expression in adipose
tissues from women with GDM [19, 20]. In extension to
these previous reports, the present study clearly shows
altered ADIPOQ gene expression in SAT as well as VAT
of GDM, even independent of their BMI. While the de-
crease in mRNA levels was relatively similar in both
SAT and VAT in GDM subjects, the difference was more
pronounced in VAT. In addition, maternal glucose levels
were associated with VAT mRNA only indicating a particu-
lar regulatory role of VAT ADIPOQ gene expression on
maternal glycemia. As the differential mRNA profiles are
possibly a consequence of altered transcriptional mecha-
nisms, analysis of regulatory factors appears critical to bet-
ter understand the potential causes of this observation.
To the best of our knowledge, this is the first study de-
termining DNA methylation of ADIPOQ in adipose
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tissues from women with GDM and NGT. Both fat de-
pots were characterized by overall similar DNA methyla-
tion patterns irrespective of women’s glucose tolerance.
Furthermore, methylation of R2 and R3 was inversely as-
sociated with gene expression in SAT and VAT indicat-
ing the functional relevance of these two regions. While
region R2 is able to serve as a transcription binding site
for a variety of factors [23], a regulatory function of the
intronic region R3 is unknown [22]. Interestingly, VAT
R3 CpG1 was hypermethylated in GDM subjects as
compared to controls. As DNA methylation at this site
was correlated inversely with gene expression, this alter-
ation might contribute to reduced transcription in VAT
of women with GDM. However, the mean group differ-
ence was rather small, and therefore, it remains open if
it plays, indeed, a relevant role. Thus, alterations of other
regulatory mechanisms may be responsible for decreased
mRNA levels. Moreover, there were obvious adipose
tissue-specific DNA methylation patterns that were not
associated with and reflected in DNA methylation of
MB cells, even though only R3 CpG1 showed a consist-
ent signature in MB and VAT across groups. Therefore,
based on our findings, blood DNA methylation of inves-
tigated regions can hardly serve as a reliable indicator/
biomarker for adipose tissue methylation. Beyond the
addressed study subject, this observation appears to de-
serve particular attention.
Exposure to a diabetic intrauterine environment may
program the offspring for a higher susceptibility for “dia-
besity” development later in life [4, 25]. Alterations of
DNA methylation are suggested to contribute to this
phenomenon [25]. Pioneer work by Bouchard et al. [22]
observed the relationships between maternal glucose
levels at oGTT and placental DNA methylation of the
two regions investigated here (R1 and R3). Intriguingly,
we found indeed a significantly altered methylation pat-
tern of R2 and R3, but not R1, in CB of GDM newborns.
Moreover, maternal glucose at oGTT and/or at delivery
was related to CB DNA methylation levels of R2 and, in
particular, R3, which may suggest a potential influence
of maternal hyperglycemia itself. Of note, R2 and R3
may be involved in gene regulation, as indicated by the
adipose tissue data. In all cases, however, the mean
methylation differences were rather small, as in other
studies [31–33]. Paradoxically, the region R2 was con-
sistently hypomethylated here, but R3 was hypermethy-
lated at each analyzed CpG site in CB of GDM
newborns. Considering the functional relevance of R2 as
recently described [23], lower methylation could fit with
the slightly higher circulating adiponectin levels ob-
served in the GDM offspring. Since it is unclear whether
ADIPOQ is expressed in CB cells, our ability to speculate
about functional consequences of the observed alter-
ations for ADIPOQ expression in the offspring is limited.
The associations found between methylation of R2 and
(relative) birth weight seem to fit with the idea that
lower methylation in R2 is related to increased ADIPOQ
expression. Furthermore, it has been shown that CB
adiponectin is positively associated with birth weight
[27, 29]. However, the positive relation between methy-
lation of R3 and CB adiponectin appears not in agree-
ment with a functional role of R3, as higher methylation
would result in lower expression. Notably, R3 CpG1 was
hypermethylated in three tissues, i.e., VAT, MB, and CB, in
the GDM group and might therefore have a diagnostic/
predictive potential for adiponectin dysregulation. Never-
theless, we cannot exclude that this finding has no de-
cisive functional implications for the offspring, as CB
adiponectin was not significantly altered in GDM off-
spring, and apparently, blood cells did not reflect maternal
adipose tissue methylation. Interestingly and worth noting,
however, a very recent study in adults born to mothers
with GDM is showing significantly increased ADIPOQ
DNA methylation, accompanied with lower gene expres-
sion in SAT [34].
A study limitation is that whole tissue biopsies were
investigated, a common approach in the majority of such
studies [19, 20, 22], and therefore, we cannot exclude
that differences in cell-type heterogeneity between tis-
sues, subjects, or GDM patients and controls influenced
the molecular results. Furthermore, as adipose tissues
are the major source of adiponectin, our expression ana-
lyses were solely in SAT and VAT and not in maternal
and fetal blood cells, limiting our ability to evaluate the
functional implications of blood DNA methylation on
transcription. Still, as adipose tissues and other fetal tis-
sues have been identified as tissues of origin for adipo-
nectin in the newborn [35], the relative contribution of
CB adiponectin expression, if there is any, to circulating
levels might be comparably small. Larger human studies
might be beneficial to evaluate the sex-specific effects of
the role of fetal adiponectin and DNA methylation pro-
files in fetal tissues.
Conclusions
In conclusion, reduced adipose tissue ADIPOQ expression
appears to be a genuine pathogenic co-factor in GDM,
even irrespective of the maternal weight status. Accom-
panying, the DNA methylation of the two functional char-
acterized regions (R2 and R3) is altered in CB cells of
GDM-exposed newborns. Thus, future studies, especially
in adiponectin-source tissues, should further evaluate the
pathogenic, diagnostic, and/or therapeutic capability of
adiponectin in GDM as well as the potential intrauterine-
acquired DNA methylation patterns that affect gene tran-
scription and, consequently, the phenotypic outcome and
“diabesogenic” risk of GDM offspring.
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Methods
This investigation is part of the prospective observa-
tional “Early CHARITÉ (EaCH)” cohort study [36].
Twenty-five women with GDM and 30 women with
NGT were prospectively recruited before the scheduled
delivery of singletons via cesarean section (CS) at the
Clinic of Obstetrics of the Charité – Universitätsmedizin
Berlin, Campus Virchow-Klinikum, Germany. Recruitment,
exclusion criteria, standardized procedures, analytical me-
thods, etc. are described in detail elsewhere [36]. The
groups were matched for maternal age, ethnic origin,
socio-economic status (SES), parity, and, in particular, pre-
pregnancy BMI. Research design and methods were con-
ducted in accordance with the Declaration of Helsinki,
revised in 2004, and approved by the local Ethics Commit-
tee (EA2/026/04). Informed written consent was obtained
from all subjects.
Subject data
Maternal data were collected as previously described
[36]. Briefly, maternal height and weight before concep-
tion and the last measured weight within 1 week prior to
delivery were abstracted from the “Mutterpass” (a stan-
dardized maternity record in Germany), and the BMI was
calculated. Total gestational weight gain (GWG) was cal-
culated as the difference between prepregnancy weight
and nearest weight to delivery. Furthermore, to estimate
the genuine maternal body habitus, net GWG was gener-
ated by subtracting birth weight and placental weight from
women’s total GWG. GDM screening was performed be-
tween the 24th and 28th week of gestation according to
the national guidelines at the time of recruitment [37, 38].
Patients with GDM were treated either by dietary therapy
alone or in combination with insulin therapy (n = 13) to
achieve glucose targets according to the abovementioned
guidelines [37, 38].
Newborn characteristics were abstracted from medical
records. Anthropometric outcomes included birth weight,
relative birth weight (g/cm), and macrosomia (defined as
birth weight ≥ 4000 g). Further clinical parameters, includ-
ing placental weight, were determined as described else-
where [36].
Blood and adipose tissue sampling
Fasting maternal venous blood was collected prior to
CS and venous umbilical CB was drawn immediately
after birth and cord clamping. For further analyses,
fractions of plasma and blood cells were stored separ-
ately at − 80 °C. Paired abdominal SAT and omental
VAT biopsies were obtained during CS, snap frozen in
liquid nitrogen, and stored at − 80 °C. For technical rea-
sons, in one GDM subject, it was not possible to collect
the VAT sample.
Blood hormone and metabolite analyses
Total plasma adiponectin was determined using a spe-
cific commercially available ELISA (Cat# RD191023100,
BioVendor, Brno, Czech Republic). Plasma insulin, C-pep-
tide, and leptin levels were measured using commercially
available radioimmunoassays (insulin, Cat# RIA-1249;
C-peptide, Cat# RIA-1252; leptin, Cat# RIA-1624; DRG
Instruments, Marburg, Germany). The following are the
inter-assay coefficients of variance: adiponectin 6.0%, insu-
lin 3.4–6.0%, C-peptide 2.4–9.3%, and leptin 3.6–6.2%.
Plasma glucose and triglyceride concentrations were quan-
tified using the oxidase-peroxidase and the glyceride-3-
phosphatoxidase-peroxidase method (both obtained from
Dr. Lange, Berlin, Germany). As an indicator of insulin re-
sistance, the homeostatic model assessment (HOMA-IR)
was calculated [39].
Adipose tissue gene expression analyses
Total RNA was isolated from 100 mg adipose tissue
using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol, in-
cluding DNase treatment (Qiagen). Quantity and purity
were assessed with a spectrophotometer (NanoDrop 1000,
Thermo Scientific, Wilmington, DE, USA). Quality was
evaluated using the Bioanalyzer 2100 (Agilent Technolo-
gies, Santa Clara, CA, USA). Overall, the samples showed
high RNA integrity numbers (RIN; SAT: 7.8 ± 0.1, VAT:
7.7 ± 0.1); however, two VAT samples of the GDM group
had to be excluded due to lower RNA quality (RIN < 6).
For cDNA synthesis, 300 ng RNA was reverse transcribed
using the iScript kit (Bio-Rad, Hercules, CA, USA) as rec-
ommended by the manufacturer. Quantitative real-time
PCR was performed using TaqMan technology (Applied
Biosystems, Waltham, MA, USA) in combination with a
7500 instrument (Applied Biosystems). All samples were
run in triplicate, and all plates included respective controls
to ensure run quality and confirm the absence of contam-
ination. Protocol conditions were as follows: denaturation
at 95 °C for 10 min, followed by 40 two-step cycles at 95 °
C for 15 s and 60 °C for 1 min. A pre-designed exon-exon
spanning TaqMan primer assay for ADIPOQ was obtained
from Applied Biosystems (ID: Hs00605917_m1) and amp-
lified in dualplex with the housekeeping gene peptidylpro-
lyl isomerase A (PPIA; ID: Hs99999904_m1). ADIPOQ
gene expression was normalized using the 2−ΔCt method,
including the correction for amplification efficiency calcu-
lated from standard curves of each primer set. Gene ex-
pression of PPIA was stable, as in a previous housekeeping
gene study for adipose tissue [40], and was identical be-
tween the groups in both fat depots (SAT: 23.76 ± 0.09 vs.
23.72 ± 0.12; VAT: 23.39 ± 0.10 vs. 23.51 ± 0.08; NGT vs.
GDM; arbitrary units). As both adipose tissue types con-
tribute to circulating adiponectin, a sum of SAT and VAT
mRNA levels was calculated and additionally analyzed.
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DNA methylation analyses
Genomic DNA was extracted from 30 mg adipose tissue
and 1 mL blood, respectively, using the Genomic DNA-
Tissue kit or the Quick-gDNA Blood kit (both obtained
from Zymo Research, Irvine, CA, USA), following the
manufacturer’s protocols. Quantity and purity of DNA
were assessed with NanoDrop (Thermo Scientific). So-
dium bisulfite treatment was performed on 400 ng DNA
using the EZ DNA Methylation-Gold kit (Zymo Research)
as recommended by the manufacturer. In silico analyses
revealed that the ADIPOQ promoter has no classical CpG
island and contains a low number of CpG sites (chromo-
somal location chr3:186,556,516-186,580,200, UCSC
Genome browser on human Feb. 2009, GRCh37/hg19
assembly). Furthermore, characterized transcription
factor binding sites, e.g., PPRE, SRE, include no CpG
site [21, 41–44]. Thus, assays were selected based on
recently published regions, obviously important for
ADIPOQ gene regulation [22, 23]. The following re-
gions were analyzed: R1 and R3 (similar to region “C”
and “E” in Bouchard et al. [22]) and R2 (similar to “R2”
in Kim et al. [23]). Methylation assays were designed using
the PyroMark Assay Design Software v. 2.0 (Qiagen), and
detailed information is given in Additional file 1: Table S1.
Pyrosequencing was performed on amplified PCR prod-
ucts with the PyroMark Q24 pyrosequencer (Qiagen) as
previously described [45]. Percent methylation was ana-
lyzed across individual CpG sites located within the fol-
lowing regions of interest: R1 (four CpGs), R2 (three
CpGs), and R3 (three CpGs). Bisulfite treatment and pyro-
sequencing assays were tested and reproducibility vali-
dated using duplicate samples, various tissue types, and
methylation scales (0–100%).
Statistical analyses
Data are presented as means ± SEM or number and per-
centage. Continuous variables were evaluated for normal
distribution using Shapiro-Wilk tests. If necessary, skewed
data were logarithmically transformed to achieve normal
distribution. Group comparisons were analyzed by un-
paired t test or Mann-Whitney U test or chi-squared/Fish-
er’s exact test, as appropriate. ANCOVA was used to
adjust for maternal BMI or newborn sex. To assess the as-
sociations between clinical and/or endocrine parameters
and DNA methylation, Spearman’s correlation coefficients
(r) were calculated. Pearson’s correlations coefficients (R)
were used to test the relationships between molecular
data, i.e., circulating adiponectin levels, gene expression,
and DNA methylation. Potential confounding effects of
maternal BMI were checked with partial Pearson’s correla-
tions. Statistical analyses were performed using SPSS v.
24.0 (IBM, Armonk, NY, USA). A P value < 0.05 was con-
sidered significant (two-tailed).
Additional file
Additional file 1: Table S1. Primer information for DNA methylation
analyses. (DOCX 14 kb)
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